Cargando…

Precise quantitative evaluation of pharmacokinetics of cisplatin using a radio-platinum tracer in tumor-bearing mice

The platinum-based antineoplastic drug cisplatin is commonly used for chemotherapy in clinics. This work aims to demonstrate a radio-platinum tracer is useful for precisely quantifying small amounts of platinum in pharmacokinetics studies. METHODS: A cisplatin radiotracer (radio-cisplatin) was synth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Obata, Honoka, Tsuji, Atsushi B., Sudo, Hitomi, Sugyo, Aya, Minegishi, Katsuyuki, Nagatsu, Kotaro, Ogawa, Mikako, Zhang, Ming-Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575570/ https://www.ncbi.nlm.nih.gov/pubmed/36120823 http://dx.doi.org/10.1097/MNM.0000000000001614

Ejemplares similares

In Vitro Evaluation of No-Carrier-Added Radiolabeled Cisplatin ([(189, 191)Pt]cisplatin) Emitting Auger Electrons
por: Obata, Honoka, et al.
Publicado: (2021)

Synthesis of no-carrier-added [(188, 189, 191)Pt]cisplatin from a cyclotron produced (188, 189, 191)PtCl(4)(2−) complex
por: Obata, Honoka, et al.
Publicado: (2021)

Novel Auger-Electron-Emitting (191)Pt-Labeled Pyrrole–Imidazole Polyamide Targeting MYCN Increases Cytotoxicity and Cytosolic dsDNA Granules in MYCN-Amplified Neuroblastoma
por: Obata, Honoka, et al.
Publicado: (2023)

Development of Novel (191)Pt-Labeled Hoechst33258: (191)Pt Is More Suitable than (111)In for Targeting DNA
por: Obata, Honoka, et al.
Publicado: (2022)

Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
por: Sudo, Hitomi, et al.
Publicado: (2019)

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2021)

Evaluation of (89)Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2013)

Development of a Stable Peptide-Based PET Tracer for Detecting CD133-Expressing Cancer Cells
por: Hu, Kuan, et al.
Publicado: (2021)

α‐particle therapy for synovial sarcoma in the mouse using an astatine‐211‐labeled antibody against frizzled homolog 10
por: Li, Huizi Keiko, et al.
Publicado: (2018)

Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor Uptake
por: Sugyo, Aya, et al.
Publicado: (2020)

DNA Repair Inhibitors: Potential Targets and Partners for Targeted Radionuclide Therapy
por: Obata, Honoka, et al.
Publicado: (2023)

Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019)

Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
por: Yoshida, Chisato, et al.
Publicado: (2013)

Immunotargeting of Integrin α(6)β(4) for Single-Photon Emission Computed Tomography and Near-Infrared Fluorescence Imaging in a Pancreatic Cancer Model
por: Aung, Winn, et al.
Publicado: (2016)

FZD10‐targeted α‐radioimmunotherapy with (225)Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model
por: Sudo, Hitomi, et al.
Publicado: (2021)

Evaluation of Efficacy of Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
por: Sugyo, Aya, et al.
Publicado: (2015)

Radioimmunotherapy of pancreatic cancer xenografts in nude mice using (90)Y-labeled anti-α(6)β(4) integrin antibody
por: Aung, Winn, et al.
Publicado: (2016)

Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with (90)Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer
por: Sugyo, Aya, et al.
Publicado: (2018)

Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression
por: Sudo, Hitomi, et al.
Publicado: (2020)

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3
por: Takakusagi, Yoichi, et al.
Publicado: (2021)

Uniform intratumoral distribution of radioactivity produced using two different radioagents, (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) and (64)Cu-ATSM, improves therapeutic efficacy in a small animal tumor model
por: Jin, Zhao-Hui, et al.
Publicado: (2018)

Combined treatment of pancreatic cancer xenograft with (90)Y-ITGA6B4-mediated radioimmunotherapy and PI3K/mTOR inhibitor
por: Aung, Winn, et al.
Publicado: (2017)

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice
por: Sugyo, Aya, et al.
Publicado: (2022)

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.
por: Guchelaar, H. J., et al.
Publicado: (1992)

Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018)

(111)In-labeled anti-cadherin17 antibody D2101 has potential as a noninvasive imaging probe for diagnosing gastric cancer and lymph-node metastasis
por: Fujiwara, Kentaro, et al.
Publicado: (2019)

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
por: Peng, B., et al.
Publicado: (1997)

Simple Trans-Platinum Complex Bearing 3-Aminoflavone Ligand Could Be a Useful Drug: Structure-Activity Relationship of Platinum Complex in Comparison with Cisplatin
por: Fabijańska, Małgorzata, et al.
Publicado: (2020)

Crystallographic study of PET radiotracers in clinical evaluation for early diagnosis of Alzheimers
por: Altomare, Angela, et al.
Publicado: (2014)

Cyclotron production of (225)Ac from an electroplated (226)Ra target
por: Nagatsu, Kotaro, et al.
Publicado: (2021)

Immuno-PET Imaging of HER3 in a Model in which HER3 Signaling Plays a Critical Role
por: Yuan, Qinghua, et al.
Publicado: (2015)

Plasma radio-metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography
por: Li, Fiona, et al.
Publicado: (2020)

Immuno-OpenPET: a novel approach for early diagnosis and image-guided surgery for small resectable pancreatic cancer
por: Yoshii, Yukie, et al.
Publicado: (2020)

In Vitro and In Vivo Cell Uptake of a Cell-Penetrating Peptide Conjugated with Fluorescent Dyes Having Different Chemical Properties
por: Takakura, Hideo, et al.
Publicado: (2021)

Correction: Takakura et al. In Vitro and In Vivo Cell Uptake of a Cell-Penetrating Peptide Conjugated with Fluorescent Dyes Having Different Chemical Properties. Cancers 2021, 13, 2245
por: Takakura, Hideo, et al.
Publicado: (2022)

Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016)

Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer
por: Takekuma, Munetaka, et al.
Publicado: (2015)

Radioactive Tracer Studies of Red Cell Destruction in Rats bearing a Transplantable Tumour
por: Belcher, E. H., et al.
Publicado: (1960)

Radio-frequency plasma polymerized biodegradable carrier for in vivo release of cis-platinum
por: Bhatt, Sudhir, et al.
Publicado: (2016)

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer
por: Masadah, Rina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_avom70jfmi710ot457vrcfeq2m